The ADVANCE trial evaluates the effects of intensive blood pressure lowering and blood glucose lowering treatments in type 2 diabetic patients on the incidence of macrovascular and microvascular complications of diabetes. The glucose lowering arm revealed a statistically significantly reduced incidence of microvascular complications (primarily nephropathy) and a statistically nonsignificantly reduced incidence of macrovascular accidents in the intensively treated group compared with the standard therapy group.